Rallybio presents Phase 1 single ascending dose data for RLYB116

Rallybio presented clinical data in a poster from the Phase 1 first-in-human single ascending dose clinical study in healthy participants of RLYB116. RLYB116 is an innovative potentially long-acting, subcutaneously injected inhibitor of C5 in development for the treatment of patients with complement-mediated diseases. The poster presentation took place at the 29th International Complement Workshop, in Newcastle, U.K. The data demonstrated that single-dose administration of RLYB116 at the two higher doses of 100 mg and 300 mg resulted in maximum exposures of greater than 1 microM and 3 microM, respectively, and greater than 99% reductions in free C5 concentrations. Subcutaneously administered RLYB116 was observed to be generally well-tolerated as a single 100 mg or 300 mg dose, with mild to moderate adverse events and no drug-related serious adverse events.